- |||||||||| TG 4040 / Transgene
Journal, Combination therapy: Optimized Hepatitis C Virus (HCV) E2 Glycoproteins and their Immunogenicity in Combination with MVA-HCV. (Pubmed Central) - Aug 9, 2020
Our findings revealed how two E2 viral proteins that differ in their capacity to form aggregates are able to enhance to different extent the HCV-specific cellular and humoral immune responses, either alone or in combination with MVA-HCV. These combined protocols of MVA-HCV/E2 could serve as a basis for the development of a more effective HCV vaccine.
- |||||||||| TG 4040 / Transgene
Preclinical, Journal: Potent Anti-Hepatitis C (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-launched RNA Replicons and MVA-HCV. (Pubmed Central) - Nov 21, 2019
Immunization of mice with the DREP vaccines as the priming immunization followed by a heterologous boost with a recombinant modified vaccinia virus Ankara (MVA) vector expressing the nearly full-length genome of HCV (MVA-HCV) induced potent and long-lasting HCV-specific CD4 and CD8 T cell immune responses that were significantly stronger than those of a homologous MVA-HCV prime/boost immunization, with the DREP-e-HCV/MVA-HCV combination the most immunogenic regimen...Here, we describe for the first time the generation of novel vaccines against HCV based on alphavirus DNA replicons expressing HCV antigens. We demonstrate that potent T cell immune responses, as well as humoral immune responses against HCV can be achieved in mice by using a combined heterologous prime/boost immunization protocol consisting in the administration of alphavirus replicon DNA vectors as a prime followed by a boost with a recombinant modified vaccinia virus Ankara vector expressing HCV antigens.
- |||||||||| TG 4040 / Transgene
Enrollment change: TG4040 in Patients With Chronic HCV (clinicaltrials.gov) - Jan 23, 2019
P1, N=0, Withdrawn,
We demonstrate that potent T cell immune responses, as well as humoral immune responses against HCV can be achieved in mice by using a combined heterologous prime/boost immunization protocol consisting in the administration of alphavirus replicon DNA vectors as a prime followed by a boost with a recombinant modified vaccinia virus Ankara vector expressing HCV antigens. N=85 --> 0
|
